Progyny Study Reveals Gap in Women’s Health Benefit Perceptions
A Progyny-Dynata survey of 1,202 women and 252 benefits decision-makers at large US companies reveals a stark disconnect between...
A Progyny-Dynata survey of 1,202 women and 252 benefits decision-makers at large US companies reveals a stark disconnect between...
Arbor Biotechnologies has dosed the first patient in its Phase 1/2 rephine trial of ABO-101, a CRISPR gene editing...
Tenaya Therapeutics announced positive recommendations from independent Data Safety Monitoring Boards (DSMBs) for its two cardiovascular gene therapy trials:...
VYNE Therapeutics’ Phase 2b trial of Repibresib gel for nonsegmental vitiligo failed to meet its primary endpoint of F-VASI50...
CorTec GmbH has implanted its Brain Interchange™ brain-computer interface (BCI) system in a human for the first time. The...
Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a monoclonal antibody targeting the...
Pharmazz has initiated its pivotal Phase 3 RESPECT-ETB trial evaluating sovateltide, a first-in-class endothelin-B receptor agonist, in acute cerebral...
Fulcrum Therapeutics reported positive 12-week data from the 12mg dose cohort of its Phase 1b PIONEER trial of pociredir...
Emergent BioSolutions announced the publication of a review article on the use of its investigational antiviral drug, brincidofovir, for...
NetraMark Holdings Inc., an AI company specializing in clinical trials, and AlgoTherapeutix SAS (AlgoTx), a biotech company developing therapies...